Sandbox southuniversity6

From Proteopedia
Revision as of 01:19, 5 June 2012 by Arthur Cox (talk | contribs)
Jump to navigation Jump to search

Medicinal Chemistry of HIV Integrase InhibitorsMedicinal Chemistry of HIV Integrase Inhibitors

When AIDS was first discovered in the 1980s, an individual's prognosis was grim, with a life expectancy on the order of 10 years. With development of effective antiviral drugs, this has increased up to 50 years or more. The HIV virus encodes several enzymes that are drug targets. The first effective drugs that were developed inhibit reverse transcriptase. The next drugs that were developed inhibit another enzymes that the virus encodes, HIV protease. The drugs that are under consideration here, the HIV integrase inhibitors are the most recently available class. Using multiple classes of drugs in combination has turned out to be a vital factor in effective treatment of HIV infection. For this reason, new integrase inhibitors have been avidly pursued by medicinal chemists across the globe.

Some of the first experimental compounds that were developed were members of a class called β-diketo acids, since there are 2 carbonyl groups located beta to a carboxylic acid functional group. Although they are referred to as "diketo acids (DKAs)", in solution they can also exist as the tautomeric enols. This is important, since it is the enol tautomer that is proposed to be species that actually binds to the integrase enzyme.


keto-enol tautomerism of L-731,988 a beta-diketo acid integrase inhibitor
keto-enol tautomerism of L-731,988 a beta-diketo acid integrase inhibitor

The functional groups proposed for the pharmacophore of the DKAs includes a aromatic ring located a certain distance from hydrogen bond donating and accepting groups. Looking at the enol tautomer of L-731,988, how many hydrogen bond donors do you see?


raltegravir (isentress)
raltegravir (isentress)

Compare the structure of raltegravir (Isentress)to that of the prototype DKA shown above. Can you see a hydrophobic group at one end of the molecule, with hydrogen bond donor, acceptor, and donor functional groups next to each other?

The structure to the left is the first HIV integrase that has made it's way to market, raltegravir (Isentress).

Structure of the first HIV integrase inhibitor to market, raltegravir (PDB entry RLT)

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Arthur Cox